Skip to main content
. 2022 Sep 17;17(5):517–527. doi: 10.1007/s11523-022-00906-w

Fig. 1.

Fig. 1

Distribution of patients. FGFR2 fibroblast growth factor receptor 2, iCCA intrahepatic cholangiocarcinoma